Alkermes posts Q3 2026 revenue of $480.1 million, touts orexin pipeline progress
The company highlighted ADHD proof-of-concept data and a new phase 2 depression trial for its orexin 2 receptor agonists alongside quarterly earnings.
Alkermes plc reported third quarter 2026 financial results on November 3, 2026, posting total revenues of $480.1 million, GAAP net income of $16.3 million and Adjusted EBITDA of $120.1 million.
President and Chief Executive Officer Blair Jackson pointed to pipeline progress in the company's neuroscience franchise. He said the company continued to advance its portfolio of orexin 2 receptor agonists in central disorders of hypersomnolence and other neuropsychiatric conditions, highlighting recent clinical proof-of-concept data in ADHD and the initiation of a phase 2 study in major depressive disorder.1 Jackson said the company expects several important clinical data readouts over the year ahead as it builds evidence for orexin biology across multiple neuropsychiatric disorders.1
Total LYBALVI prescriptions grew 18% compared to the third quarter of 2025.1 At the end of the third quarter, approximately 4,100 patients were on LUMRYZ therapy.1
Fact check notes
- Sentence removed
On the commercial side, quarterly net sales for proprietary products included $127.6 million for VIVITROL, $103.9 million for ARISTADA, $95.9 million for LYBALVI and $89.9 million for LUMRYZ.
a figure with no citation - Sentence removed
Alkermes reiterated its financial expectations for 2026, as set forth in its press release dated July 28, 2026.
copied source wording - Sentence removed
On the balance sheet, the company's cash, cash equivalents and total investments stood at $787.6 million as of September 30, 2026, up from $588.4 million at December 31, 2025, according to the filing's financial tables.
a figure with no citation - Sentence removed
The quarter's results also reflected costs tied to the acquisition of Avadel Pharmaceuticals plc, including $20.2 million in accelerated vesting expense for former Avadel employees that vested upon the deal's closing.
a figure with no citation
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.